<DOC>
	<DOCNO>NCT00002314</DOCNO>
	<brief_summary>To study effect Ro 24-7429 tumor growth patient HIV-related Kaposi 's sarcoma . To study safety tolerance , effect HIV replication , immunologic effect Ro 24-7429 patient population . To explore relationship exposure Ro 24-7429 metabolite antitumor antiviral activity drug toxicity .</brief_summary>
	<brief_title>A Study Ro 24-7429 Patients With HIV-Related Kaposi 's Sarcoma</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Sarcoma , Kaposi</mesh_term>
	<criteria>Inclusion Criteria Patients must : HIV seropositivity . Biopsyproven mucocutaneous Kaposi 's sarcoma few 50 skin lesion measurable disease . No active opportunistic infection . NOTE : Patients CD4 count &gt; = 200 cells/mm3 must prior opportunistic infection , well active opportunistic infection . Life expectancy least 24 week . Stable weight ( +/ 2 kg ) 28 day prior study entry . Exclusion Criteria Coexisting Condition : Patients follow symptoms condition exclude : Other active malignancy ( except basal cell carcinoma skin situ cervical cancer ) . Known suspected hypersensitivity benzodiazepine . Evidence clinically significant cardiac , respiratory , hepatic , gastrointestinal , endocrine , hematologic , psychiatric , neurologic , dermatologic , allergic disease determine investigator . Ongoing diarrhea ( &gt; two liquid stool per day ) . Grade 2 bad sign symptom AIDS Dementia Complex . Alteration mental status may interfere study compliance . Concurrent Medication : Excluded : AZT , ddI , ddC . Experimental antiretrovirals . Biologic response modifier immunomodulating agent ( e.g. , interferon ) . Colony stimulate factor ( erythropoietin , GMCSF , GCSF ) . Ganciclovir . Foscarnet . H2 antagonist ( cimetidine , ranitidine , famotidine , nizatidine ) . Omeprazole . Benzodiazepines . Any investigational compound . Ongoing systemic treatment corticosteroid ( replacement therapy adrenal insufficiency shortterm therapy 28 day bronchial asthma ) . Cytotoxic chemotherapy ( systemic local ) . Drugs know cause systemic toxicity , avoidable ( e.g. , myelosuppressive , hepatotoxic , nephrotoxic , neurotoxic drug ) . Paromomycin sulfate . Chronic suppressive therapy CMV and/or MAI . Patients follow prior condition exclude : History serious adverse reaction benzodiazepine . Prior Medication : Excluded : Interferons immune modulators within 4 week prior study entry . Prior systemic cytotoxic chemotherapy ( patient CD4 count &gt; = 200 cells/mm3 ) . Benzodiazepines within 14 day prior study entry . Intralesional chemotherapy Kaposi 's sarcoma within 2 week prior study entry . Therapy antiretroviral drug ( include AZT , ddI , ddC , d4T ) investigational drug within 14 day prior study entry . Localized radiotherapy . Radiotherapy ( localize ) . Active drug alcohol abuse .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 1993</verification_date>
	<keyword>Sarcoma , Kaposi</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>Antineoplastic Agents</keyword>
	<keyword>Gene Products , tat</keyword>
</DOC>